Peripheral inflammation and cognitive aging

Inflammation in Psychiatry

Volumn 28, Issue , 2013, Pages 175-187

  Lim, Alvin ^a   Krajina, Katarina ^a   Marsland, Anna L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925698396     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000346362     Document Type: Chapter

References (105)

1. Buckner RL: Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 2004;44:195-208.
2. Davis HP, et al: Acquisition, recall, and forgetting of verbal information in longterm memory by young, middle-aged, and elderly individuals. Cortex 2003;39:1063-1091.
3. Huh TJ, et al: Response bias and aging on a recognition memory task. J Int Neuropsychol Soc 2006;12:1-7.
4. Wecker NS, et al: Mental flexibility: age effects on switching. Neuropsychology 2005;19:345-352.
5. Salthouse TA: When does age-related cognitive decline begin? Neurobiol Aging 2009;30:507-514.
6. Barberger-Gateau P, et al: Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? J Am Geriatr Soc 1999;47:456-462.
7. Yaffe K: Metabolic syndrome and cognitive disorders: is the sum greater than its parts? Alzheimer Dis Assoc Disord 2007;21:167-171.
8. Yaffe K, et al: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242.
9. Brown GC, Neher JJ: Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010;41:242-247.
10. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636.
11. Bataille R, Klein B: C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 1992;35:982-983.
12. Maggio M, et al: Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006;61: 575-584.
13. Bluthe RM, et al: Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology 1994;19:197-207.
14. Rachal Pugh C, et al: The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci Biobehav Rev 2001;25:29-41.
15. Dantzer R: Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004;500:399-411.
16. Lee JW, et al: Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008;5:37.
17. Tracey KJ: The inflammatory reflex. Nature 2002;420:853-859.
18. Ek M, et al: Inflammatory response: pathway across the blood-brain barrier. Nature 2001;410:430-431.
19. Laflamme N, Rivest S: Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain. J Neurochem 1999;73:309-321.
20. Streit WJ, Mrak RE, Griffin WS: Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 2004;1:14.
21. Prinz M, Mildner A: Microglia in the CNS: immigrants from another world. Glia 2011;59:177-187.
22. Aloisi F: Immune function of microglia. Glia 2001;36:165-179.
23. Dickson DW, et al: Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993;7:75-83.
24. Hanisch U-K: Microglia as a source and target of cytokines. Glia 2002;40:140-155.
25. Gadient RA, Otten U: Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. Brain Res 1994;637:10-14.
26. Vallieres L, et al: Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 2002;22:486-492.
27. Vitkovic L, et al: Cytokine signals propagate through the brain. Mol Psychiatry 2000;5:604-615.
28. McAfoose J, Baune BT: Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009;33:355-366.
29. Reichenberg A, et al: Cytokineassociated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
30. Yirmiya R, Goshen I: Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011;25:181-213.
31. Oitzl MS, et al: Interleukin-1 beta, but not interleukin-6, impairs spatial navigation learning. Brain Res 1993;613:160-163.
32. Gibertini M, et al: Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1-beta. Brain, Behavior, and Immunity 1995;9:113-128.
33. Song C, Horrobin D: Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration. J Lipid Res 2004;45:1112-1121.
34. Lacosta S, Anisman H, Merali Z: Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav Neurosci 1999;113:1030-1041.
35. Gibertini M: Cytokines and cognitive behavior. NeuroImmunoModulation 1998;5:160-165.
36. Heyser CJ, et al: Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 1997;94:1500-1505.
37. Balschun D, et al: Interleukin-6: a cytokine to forget. FASEB J 2004;18:1788-1790.
38. Frank MG, et al: Microglia serve as a neuroimmune substrate for stressinduced potentiation of CNS proinflammatory cytokine responses. Brain Behav Immun 2007;21:47-59.
39. Perry VH, Cunningham C, Holmes C: Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007;7:161-167.
40. Ben Menachem-Zidon O, et al: Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolation-induced impairment in memory and neurogenesis. Neuropsychopharmacology 2008;33:2251-2262.
41. Simen AA, et al: Cognitive dysfunction with aging and the role of inflammation. Ther Adv Chron Dis 2011;2:175-195.
42. Krabbe KS, Pedersen M, Bruunsgaard H: Inflammatory mediators in the elderly. Exp Gerontol 2004;39:687-699.
43. Ye SM, Johnson RW: Increased interleukin-6 expression by microglia from brain of aged mice. J Neuroimmunol 1999;93:139-148.
44. Perry VH, Matyszak MK, Fearn S: Altered antigen expression of microglia in the aged rodent CNS. Glia 1993;7:60-67.
45. Chen J, et al: Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav Immun 2008;22:301-311.
46. Sparkman NL, Johnson RW: Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. NeuroImmunoModulation 2008;15:323-330.
47. Brydon L, et al: Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun 2009;23:217-224.
48. Spath-Schwalbe E, et al: Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573-1579.
49. Swardfager W, et al: A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010;68:930-941.
50. Guerreiro RJ, et al: Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener Dis 2007;4:406-412.
51. McGeer PL, McGeer EG: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195-218.
52. Zuliani G, et al: Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007;41:686-693.
53. Licastro F, et al: Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000;103:97-102.
54. Engelhart MJ, et al: Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004;61:668-672.
55. Holmes C, et al: Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009;73:768-774.
56. Wallin K, et al: Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. J Alzheimers Dis 2012;31:669-676.
57. Schmidt R, et al: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-174.
58. Tan ZS, et al: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007;68:1902-1908.
59. van Himbergen TM, et al: Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch Neurol 2012;69:594-600.
60. Teunissen CE, et al: Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 2003;134:142-150.
61. Tilvis RS, et al: Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 2004;59:268-274.
62. Weaver JD, et al: Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002;59:371-378.
63. Yaffe K, et al: Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003;61:76-80.
64. Alley DE, et al: Inflammation and rate of cognitive change in high-functioning older adults. J Gerontol A Biol Sci Med Sci 2008;63:50-55.
65. Dik MG, et al: Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007;30:2655-2660.
66. Gustafson DR, et al: 37 years of body mass index and dementia: observations from the prospective population study of women in Gothenburg, Sweden. J Alzheimer's Dis 2012;28:163-171.
67. Hoozemans JJ, et al: Neuroinflammation in Alzheimer's disease wanes with age. J Neuroinflammation 2011;8:171.
68. Krstic D, Knuesel I: Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2012.
69. Laurin D, et al: Midlife C-reactive protein and risk of cognitive decline: a 31-year follow-up. Neurobiol Aging 2009;30:1724-1727.
70. Marsland AL, et al: Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom Med 2006;68:895-903.
71. Wechsler D: The WMS-III Administration and Scoring Manual. Antonio, The Psychological Corporation, 1997.
72. Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery. Tuscon, Neuropsychology Press, 1985.
73. Golden JC: Stroop Color and Word Test. Chicago, Stoelting, 1978.
74. Jack CR Jr, et al: Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484-489.
75. Mattay VS, et al: Neurophysiological correlates of age-related changes in working memory capacity. Neurosci Lett 2006;392:32-37.
76. Ashburner J, Friston KJ: Voxel-based morphometry-the methods. Neuroimage 2000;11:805-821.
77. Monje ML, Toda H, Palmer TD: Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003;302:1760-1765.
78. Wagner AD, et al: Building memories: remembering and forgetting of verbal experiences as predicted by brain activity. Science 1998;281:1188-1191.
79. Fazekas F, et al: Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683-1689.
80. Gunning-Dixon FM, et al: Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry 2009;24:109-117.
81. Debette S, Markus HS: The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and metaanalysis. BMJ 2010;341:c3666.
82. Baune BT, et al: Association between cytokines and cerebral MRI changes in the aging brain. J Geriatr Psychiatry Neurol 2009;22:23-34.
83. Furney SJ, et al: Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease-cytokines and MRI measures together predict disease progression. J Alzheimer's Dis 2011;26:395-405.
84. Miralbell J, et al: Structural brain changes and cognition in relation to markers of vascular dysfunction. Neurobiol Aging 2012;33:20.
85. Satizabal CL, et al: Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012;78:720-727.
86. Marsland AL, et al: Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008;64:484-490.
87. van Dijk EJ, et al: C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005;112:900-905.
88. Furney SJ, et al: Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease-cytokines and MRI measures together predict disease progression. J Alzheimers Dis 2011;3:395-405.
89. Hagmann P, et al: Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics 2006;26(suppl 1): S205-S223.
90. Le Bihan D, et al: Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001;13:534-546.
91. Giorgio A, et al: Age-related changes in grey and white matter structure throughout adulthood. Neuroimage 2010;51:943-951.
92. Wersching H, et al: Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010;74:1022-1029.
93. Schram MT, et al: Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007;55:708-716.
94. Roberts RO, et al: Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord 2010;24:11-18.
95. in t' Veld BA, et al: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
96. Jaturapatporn D, et al: Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012;2:CD006378.
97. de Craen AJ, et al: Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of dementia. Am J Epidemiol 2005;161:114-120.
98. Walther K, et al: Anti-inflammatory drugs reduce age-related decreases in brain volume in cognitively normal older adults. Neurobiol Aging 2011;32:497-505.
99. Fitzpatrick AL, et al: Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009;66:336-342.
100. Ward MA, et al: The effect of body mass index on global brain volume in middleaged adults: a cross sectional study. BMC Neurol 2005;5:23.
101. Forsythe LK, Wallace JM, Livingstone MB: Obesity and inflammation: the effects of weight loss. Nutr Res Rev 2008;21:117-133.
102. Kiecolt-Glaser JK, et al: Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 2003;100:9090-9095.
103. McEwen BS, Sapolsky RM: Stress and cognitive function. Curr Opin Neurobiol 1995;5:205-216.
104. Meyer JS, et al: Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 2000;21:161-169.
105. Rao KM, et al: Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. Am J Clin Pathol 1994;102:802-805.